But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deciphera, Allakos and Uniqure are all set for important data disclosures.